The Medical Research Future Fund (MRFF) 2025 grant outcomes has been released.

Targeting ‘undruggable’ MYC to transform cancer outcomes: the TARGET-MYC trial, an adaptive phase 2 basket trial of RNA polymerase 1 inhibition in MYC-driven solid and haematological tumours.

Around seven out of ten cancers are driven by the MYC protein, and those cancers typically do worse. Targeting MYC could advance treatment, but this has been thought impossible. Our team have developed a new approach to target MYC: a drug (PMR-116) which blocks the downstream effects of MYC in the cancer cell. We will evaluate PMR-116 in a trial which brings together various MYC driven tumour types. Our goal in targeting 'undruggable' MYC is to transform outcomes for people with MYC cancers.

Professor Mark Polizzotto, Doctor Syed Adnan Ali, Associate Professor Arun Azad, Associate Professor Marian Burr, Professor Jayesh Desai, Associate Professor Luc Furic, Professor Ross Hannan, Doctor Nadine Hein, Professor Mark Hertzberg, Doctor Charlotte Lemech, Professor Elgene Lim, Doctor Jonathan Roco Alegre (BDSI), Professor Clare Scott, Professor Eric Stone (BDSI), Associate Professor Ben Tran